We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medtronic and Alnylam Pharmaceuticals will collaborate to pursue potential therapies
designed to treat neurodegenerative disorders such as Huntington's, Alzheimer's
and Parkinson's disease.
International medical technology company Ventracor has received conditional
approval from the FDA for a feasibility study of its cardiac assist device in
Royal Philips Electronics has introduced an ultrasound system that provides
ultrasound departments that serve a diverse patient population and have a restricted
budget with advanced high definition imaging and sophisticated features previously
unavailable in their price range.
West Pharmaceutical Services, a maker of closure
systems and syringe components for use with injectable drugs, has announced
that, effective Feb. 8, it completed the sale of a substantial majority interest
in its drug delivery business to Archimedes Pharma, a new UK-based European
specialty pharma company backed by Warburg Pincus.
MatrixOne has announced that LifeScan Scotland, which makes blood glucose monitors
for diabetics, selected MatrixOne's product life cycle management technology
to accelerate product development and time-to-market.
CryoLife, a biomaterials and biosurgical device company, has entered into a
credit agreement with Wells Fargo Foothill, part of Wells Fargo & Company,
providing for a revolving credit facility in an aggregate amount equal to the
lesser of $15 million or a specified borrowing base.
Patient safety will drive the use of the next generation of active-RFID (radio
frequency identification) location tags from Radianse, an innovator of indoor
positioning solutions used to locate and associate equipment and people in hospitals.
NovaBone Products has announced that results of an independent clinical study
of 20 spine fusion surgery patients showed that the company's FDA-cleared synthetic
bone graft product, NovaBone, stimulated new bone formation on an "equivalent
basis" compared to "BMP-2" (bone morphogenic protein) when each
was used in a composite.
NeuroMetrix, a medical device company focused on the design, development and
sale of proprietary products used to diagnose neuropathies, announced it named
Brad Smith to serve as its chief financial officer, effective Feb. 14.